|
Vaccinex, Inc. (VCNX): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vaccinex, Inc. (VCNX) Bundle
In the cutting-edge world of biotechnology, Vaccinex, Inc. (VCNX) stands at the forefront of innovative immunotherapy research, targeting some of the most challenging diseases like cancer and neurodegenerative disorders. With its proprietary Vaxi-D platform and strategic focus on monoclonal antibody therapeutics, this Rochester, New York-based company is pioneering potential breakthrough treatments that could transform medical science. Dive into the comprehensive marketing mix that reveals how Vaccinex is positioning itself to revolutionize healthcare and potentially deliver hope to patients facing complex medical challenges.
Vaccinex, Inc. (VCNX) - Marketing Mix: Product
Immunotherapy Product Portfolio
Vaccinex, Inc. develops targeted immunotherapies for complex diseases with significant unmet medical needs.
| Product Category | Key Details | Development Stage |
|---|---|---|
| VCNX-A84 | Non-small cell lung cancer treatment | Clinical trials |
| Neurological Therapeutics | Potential Alzheimer's treatment | Preclinical research |
| Vaxi-D Platform | Proprietary immunotherapy technology | Ongoing development |
Product Technology Platform
Vaccinex utilizes monoclonal antibody therapeutic technologies targeting specific cellular mechanisms.
- Focuses on precision immunotherapy development
- Targets serious diseases with limited treatment options
- Develops therapies using proprietary Vaxi-D platform
Research Pipeline Characteristics
| Research Area | Target Indication | Current Status |
|---|---|---|
| Oncology | Non-small cell lung cancer | Advanced clinical trials |
| Neurodegenerative Disorders | Alzheimer's disease | Preclinical research |
Product Development Strategy
Vaccinex employs a targeted approach to developing innovative immunotherapeutic products addressing complex medical challenges.
- Utilizes advanced monoclonal antibody technologies
- Focuses on precision cellular mechanism targeting
- Develops therapies for high-unmet medical need conditions
Vaccinex, Inc. (VCNX) - Marketing Mix: Place
Headquarters and Research Facilities
Location: Rochester, New York, United States
Research and Development Infrastructure
| Facility Type | Location | Primary Focus |
|---|---|---|
| Main Research Center | Rochester, NY | Immunotherapy and Cancer Research |
| Clinical Research Facility | United States | Clinical Trials and Drug Development |
Collaborative Research Networks
- Academic Collaborations
- Pharmaceutical Research Centers
- Clinical Trial Research Institutions
Distribution Channels for Research Data
- Scientific Publications
- Medical Conferences
- Peer-Reviewed Journals
Strategic Partnerships and Market Reach
| Partnership Type | Potential Geographic Reach |
|---|---|
| Licensing Agreements | North America |
| Research Collaborations | International Research Networks |
Vaccinex, Inc. (VCNX) - Marketing Mix: Promotion
Conference Presentations
Vaccinex presents research findings at key oncology conferences, including:
| Conference | Year | Presentations |
|---|---|---|
| American Association for Cancer Research (AACR) | 2023 | 3 scientific abstracts |
| American Society of Clinical Oncology (ASCO) | 2023 | 2 research presentations |
Investor Relations Communications
Key communication channels include:
- Quarterly earnings calls
- Annual shareholder meetings
- Investor presentation decks
Scientific Publications
| Publication Metric | 2023 Data |
|---|---|
| Peer-reviewed journal publications | 4 publications |
| Total citations of company research | 87 citations |
Corporate Website Communication
Website content includes:
- Detailed research pipeline information
- Management team profiles
- Clinical trial updates
Investor Communication Metrics
| Communication Channel | 2023 Frequency |
|---|---|
| Earnings calls | 4 quarterly calls |
| Investor presentations | 6 presentations |
| Press releases | 12 releases |
Vaccinex, Inc. (VCNX) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Vaccinex, Inc. reported the following financial metrics:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $12.4 million |
| Cash and Cash Equivalents | $8.7 million |
| Stock Price (as of February 2024) | $0.32 per share |
Pricing Strategy Characteristics
Vaccinex operates as a clinical-stage biotechnology company with specific pricing considerations:
- No current commercial product revenue
- Funding primarily through stock offerings and research grants
- Stock valuation dependent on clinical trial progression
Funding Sources
| Funding Source | Amount (2023) |
|---|---|
| Research Grants | $3.1 million |
| Stock Offerings | $5.6 million |
| Strategic Partnerships | $2.3 million |
Stock Performance
Vaccinex stock performance metrics for 2023-2024:
- 52-week low: $0.22 per share
- 52-week high: $0.85 per share
- Average trading volume: 125,000 shares
Research and Development Investment
| R&D Expense Category | Amount (2023) |
|---|---|
| Total R&D Expenses | $9.2 million |
| Immunotherapy Research | $6.5 million |
| Clinical Trials | $2.7 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.